Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 22068911)

1.

The influence of interleukin-32γ on osteoclastogenesis with a focus on fusion-related genes.

Kim YG, So MW, Koo BS, Chang EJ, Song SJ, Lee CK, Yoo B.

J Clin Immunol. 2012 Feb;32(1):201-6. doi: 10.1007/s10875-011-9611-x. Epub 2011 Nov 9.

PMID:
22068911
2.

Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.

Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hosogane N, Matsuo K, Toyama Y, Suda T, Miyamoto T.

J Bone Miner Res. 2007 Jul;22(7):992-1001.

PMID:
17402846
3.

Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes.

Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B.

Arthritis Rheum. 2010 Feb;62(2):515-23. doi: 10.1002/art.27197.

PMID:
20112365
4.

NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).

Kim K, Lee SH, Ha Kim J, Choi Y, Kim N.

Mol Endocrinol. 2008 Jan;22(1):176-85. Epub 2007 Sep 20.

5.

Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression.

Kim HJ, Hong J, Jung JW, Kim TH, Kim JA, Kim YH, Kim SY.

Int Immunopharmacol. 2010 Nov;10(11):1440-7. doi: 10.1016/j.intimp.2010.08.017. Epub 2010 Sep 8.

PMID:
20831919
6.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
7.

Regulators of osteoclast differentiation and cell-cell fusion.

Miyamoto T.

Keio J Med. 2011;60(4):101-5. Review.

8.

The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.

Kim HS, Suh KS, Sul D, Kim BJ, Lee SK, Jung WW.

Int J Mol Med. 2012 Feb;29(2):169-77. doi: 10.3892/ijmm.2011.822. Epub 2011 Oct 31.

PMID:
22038020
9.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

10.

NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF.

J Biol Chem. 2007 Jun 22;282(25):18245-53. Epub 2007 May 7.

11.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
12.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

PMID:
15765185
13.

Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.

Okayasu M, Nakayachi M, Hayashida C, Ito J, Kaneda T, Masuhara M, Suda N, Sato T, Hakeda Y.

J Biol Chem. 2012 Jun 1;287(23):19229-41. doi: 10.1074/jbc.M111.323600. Epub 2012 Apr 12.

14.

Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan.

Hotokezaka H, Sakai E, Ohara N, Hotokezaka Y, Gonzales C, Matsuo K, Fujimura Y, Yoshida N, Nakayama K.

J Cell Biochem. 2007 May 1;101(1):122-34.

PMID:
17171644
15.

NFATc1: functions in osteoclasts.

Zhao Q, Wang X, Liu Y, He A, Jia R.

Int J Biochem Cell Biol. 2010 May;42(5):576-9. doi: 10.1016/j.biocel.2009.12.018. Epub 2009 Dec 24. Review.

PMID:
20035895
17.

Irreversible inhibition of RANK expression as a possible mechanism for IL-3 inhibition of RANKL-induced osteoclastogenesis.

Khapli SM, Tomar GB, Barhanpurkar AP, Gupta N, Yogesha SD, Pote ST, Wani MR.

Biochem Biophys Res Commun. 2010 Sep 3;399(4):688-93. doi: 10.1016/j.bbrc.2010.07.143. Epub 2010 Aug 5.

PMID:
20691668
18.

Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.

Amcheslavsky A, Bar-Shavit Z.

J Cell Physiol. 2006 Apr;207(1):244-50.

PMID:
16402377
19.

The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation.

Lee SH, Kim T, Jeong D, Kim N, Choi Y.

J Biol Chem. 2008 Apr 25;283(17):11526-34. doi: 10.1074/jbc.M708935200. Epub 2008 Feb 14.

20.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk